Clinical management and burden of cytomegalovirus in D+/R-Kidney transplant recipients in Canada
Current prophylaxis strategies fail to prevent CMV infection in 34% of high-risk patients. Myelotoxicity, opportunistic infection, reduced immunosuppression, and hospitalization remain common and serious complications. More effective and less toxic personalized treatment strategies are required to minimize these risks and burdens.
Authors
- Carlos Cervera (ORCID: https://orcid.org/0000-0002-0161-1749)
- Zain Chagla (ORCID: https://orcid.org/0000-0002-3619-7031)
- John S. Gill (ORCID: https://orcid.org/0000-0002-8837-6875)
- Shuguo Sun (ORCID: https://orcid.org/0000-0001-7968-2494)
- Jean Tchervenkov (ORCID: https://orcid.org/0000-0002-0359-7872)
- Paul Keown (ORCID: https://orcid.org/0000-0001-6466-8251)
- Amanda Vinson (ORCID: https://orcid.org/0000-0001-9955-8052)
- Andrew A. House (ORCID: https://orcid.org/0000-0001-7152-6163)
- Christiane Ghakis
- Soojin Kim (ORCID: https://orcid.org/0000-0003-2684-0545)
- C. El Khoury
Institutions
- Western University (CA)
- Dalhousie University (CA)
- University of British Columbia (CA)
- University of Alberta (CA)
- University of Toronto (CA)
- Merck Canada Inc. (Canada) (CA)
- McGill University (CA)
- McMaster University (CA)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-18
- DOI
- https://doi.org/10.3389/fimmu.2025.1618748
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Merck Canada